Sun Pharma files application for arthritis drug Tildrakizumab in Japan

Sun Pharma is committed to growing its global dermatology franchise, with Tildrakizumab as its lead product.

New Delhi: Sun Pharmaceutical on Thursday said it has filed an application for manufacturing and marketing authorization of Tildrakizumab, used to treat psoriasis and psoriatic arthritis, with the Japanese health authority.

The company's wholly-owned subsidiary has filed the application with Pharmaceuticals and Medical Devices Agency (PMDA), Japan, Sun Pharma said in a statement.

Also Read: Sun Pharma enters licensing agreement with CMS for arthritis drug Tildrakizumab

"Sun Pharma is committed to growing its global dermatology franchise, with Tildrakizumab as its lead product. We continue to build our pipeline and capabilities in this important therapeutic area of significant unmet need," Sun Pharma EVP & Head Global Business Development Kirti Ganorkar said.

This filing in Japan is a step forward for Sun Pharma in expanding the global franchise for the product, he added.

Also Read: Dilip Shanghvi plans comeback; Sun Pharma to develop its own medicines: Report

The recent acquisition of Pola Pharma (Pola) in Japan will help Sun Pharma leverage Pola's strong presence in the dermatology segment to commercialize Tildrakizumab post regulatory approval. The Mumbai-based drug major had announced the closure of the Pola acquisition in January 2019.

Also Read: Sun Pharma former RnD head murders family of three, then commits suicide